In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By



This article was originally published in The Rose Sheet

Executive Summary

Propylene glycol mono-t-butyl ether, a chemical used as a solvent in nail polish lacquers, cleaners and other water-reducible coatings, has been added to the California Prop 65 list of chemicals known to the state to cause cancer, Office of Environmental Health Hazard Assessment reports. Agency issued a notice of intent to list the chemical in April, citing an NTP study as its basis. Last year, NTP reviewed a technical report on propylene glycol mono-t-butyl ether and determined there is "equivocal evidence" of carcinogenic activity of the chemical in F344/N rats in a two-year inhalation study (1"The Rose Sheet" April 21, 2003, p. 7)...

You may also be interested in...

TEA Carcinogenic Link Suggested By Two Year NTP Study

Triethanolamine demonstrated "some evidence" of carcinogenic activity in a two-year dermal study of female B6C3F1 mice and "equivocal evidence" of carcinogenic activity in male mice, the National Toxicology Program states in a 1draft technical report on the ingredient

Industry Impact: Siemens Healthineers $16.4Bn Acquisition Of Varian – What Next?

Siemens Healthineers' acquisition of radiation oncology company Varian Medical Systems creates an oncology giant. Analysts disagree on whether its the right move for the companies.

Progress In Pharma’s Slow Battle Against Respiratory Syncytial Virus

Pfizer is up against AstraZeneca and Sanofi in developing competing approaches to tackling the unmet need in respiratory syncytial virus (RSV). But earlier failures mean all players will need much more data to sway regulators.




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts